Mipletamig Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Mipletamig Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: HOLD / OPTION
Decision memo
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
The central underwriting question is whether Mipletamig can convert its Bispecific T-cell Engager (BiTE) profile and CD123 x CD3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Mipletamig (query alias: Mipletamig) |
|---|---|
| Modality / target | Bispecific T-cell Engager (BiTE); CD123 x CD3; CD123 inhibitors, CD3 stimulants |
| Highest global status | Phase 1 |
| Originator | Aptevo Therapeutics, Inc. |
| Active developers | Aptevo Therapeutics, Inc. |
The MCP disease footprint includes CD123 Positive Acute Myeloid Leukemia. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT03647800 | Phase 1 | Unknown status | 136 | Part 1 - Dose Escalation: Maximum Tolerated Dose |
| NCT06634394 | Phase 1 | Recruiting | 39 | To assess the safety, tolerability, and maximum tolerated dose (MTD) of increasing doses of APVO436 in combination with venetoclax/azacitidine in patients with newly diagnosed AML |
| NCT04973618 | Phase 1 | Withdrawn | Not disclosed | Safety - Incidence of Grade 3-4 AEs and SAEs |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A dose optimization phase 1b/2 study evaluating mipletamig (formerly APVO436), a novel bispecific CD123 x CD3 ADAPTIRÒ molecule in combination therapy for the treatment of frontline acute myeloid leukemia (AML) in patients unfit for intensive chemotherapy
Phase 1/2; n=13; evaluation: Positive. Reported fields: TEAE = 6.0 Pts ; TEAE = 3.0 Pts
Mipletamig Delivers 100% Remission Rate in Cohort 3 of RAINIER Trial for AML
Phase 1/2; n=not disclosed; evaluation: Positive. Reported fields: remission = 100 %
First Patient Dosed in Aptevo's Ongoing RAINIER Trial Achieves 90% Reduction in Leukemic Blasts Within the First 30 Days of Treatment, Continues Overall Efficacy Trend Seen in Prior Mipletamig AML Studies
Phase 1/2; n=1; evaluation: Positive. Reported fields: leukemic blasts(within the first 30 days of treatment) = -90 %
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Mipletamig addresses CD123 Positive Acute Myeloid Leukemia. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Bispecific T-cell Engager (BiTE)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 14 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: CD123 x CD3 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2024-12-27 | Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc. | Phase 1 | Financial terms not disclosed |
| 2023-03-01 | Mustang Bio determined to terminated the license agreements with City of Hope, which included MB-102 (CD123), MB-103 (HER2), MB-104 (CS1) and MB-105 (PSCA) programs | Not disclosed | Financial terms not disclosed |
| 2022-12-09 | ImmunoGen and Gilead will assess the effectiveness of Pivekimab Sunirine combined with Magrolimab in treating Relapsed/Refractory Acute Myeloid Leukemia. | Phase 3 | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “CD123 binding proteins and related compositions and methods”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Cytokine-release syndrome, neurotoxicity, and infection
- Durability after deep B-cell or plasma-cell depletion
- Dose-step-up logistics, manufacturing, and outpatient feasibility
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
HOLD / OPTION
Preserve optionality until clinical differentiation, transaction economics, and freedom-to-operate are sufficiently de-risked.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 3 August 2026. Counts and status fields may change as source records update.
